Inflammatory Relapses after Immunosuppressive Drug Discontinuation in Uveitis Patients: A Survival Analysis

dc.contributor.authorGómez Gómez, Alejandro
dc.contributor.authorGarcía González, Javier
dc.contributor.authorPeiteado, Diana
dc.contributor.authorBorrego Sanz, Lara
dc.contributor.authorArriola Villalobos, Pedro
dc.contributor.authorEsteban Ortega, María del Mar
dc.contributor.authorMartín López, María
dc.contributor.authorVentura Hidalgo, María
dc.contributor.authorPérez Blázquez, Eugenio
dc.contributor.authorPato, Esperanza
dc.contributor.authorDíaz Valle, David
dc.contributor.authorMuñoz Fernández, Santiago
dc.contributor.authorRodríguez Rodríguez, Luis
dc.date.accessioned2021-08-25T09:09:37Z
dc.date.available2021-08-25T09:09:37Z
dc.date.issued2021
dc.description.abstractPurpose: To estimate the incidence rate (IR) and identify risk factors associated to inflammatory relapse after immunosuppressive drug (ISD) discontinuation in noninfectious uveitis patients. Methods: Multicenter longitudinal retrospective study, including patients from four uveitis clinics followed-up until December 2018. Hazard ratios for different variables were estimated using multivariable Cox models. Results: 32 patients (34 episodes of ISD discontinuation) were analyzed (median and maximum follow-up time: 2.4 and 19.2 years, respectively). Fourteen patients presented at least one relapse: anterior (8 patients), intermediate (5) and posterior (8). IR (95% confidence interval) of the first relapse was 14.3 (8.6–23.8) episodes per 100 patient-years (median survival time: 4.8 years). Early use of ISDs, panuveitis, and higher oral corticosteroid dosage at discontinuation were associated with higher hazards of relapse in multivariable analysis. Conclusions: Relapse is a frequent and early event after ISD discontinuation. Identifying relapse risk factors could support the physician’s decision regarding ISD discontinuation.spa
dc.description.filiationUEMspa
dc.description.impact3.728 JCR (2021) Q2, 23/62 Ophthalmologyspa
dc.description.impact1,232 SJR (2021) Q1, 21/128 Ophthalmologyspa
dc.description.impactNo data IDR 2021spa
dc.description.sponsorshipInstituto de Salud Carlos III (ISCIII), Ministerio de Sanidad, Consumo y Bienestar Social (Contrato de investigación Miguel Servet: CPII17 / 00014 a LRR).spa
dc.identifier.citationGómez-Gómez, A., García-González, J., Peiteado, D., Borrego-Sanz, L., Arriola-Villalobos, P., Esteban-Ortega, M., Martín-López, M., Ventura-Hidalgo, M., Pérez-Blázquez, E., Pato, E., Díaz-Valle, D., Muñoz-Fernández, S., & Rodríguez-Rodríguez, L. (2021). Inflammatory Relapses after Immunosuppressive Drug Discontinuation in Uveitis Patients: A Survival Analysis. Ocular Immunology and Inflammation, 29(2), 376-387. https://doi.org/10.1080/09273948.2019.1681469spa
dc.identifier.doi10.1080/09273948.2019.1681469
dc.identifier.issn0927-3948
dc.identifier.issn1744-5078
dc.identifier.urihttp://hdl.handle.net/11268/10314
dc.language.isoengspa
dc.peerreviewedSispa
dc.rights.accessRightsrestricted accessspa
dc.subject.otherUveítisspa
dc.subject.otherInmunosupresoresspa
dc.subject.unescoFarmacologíaspa
dc.subject.unescoInmunologíaspa
dc.subject.unescoOftalmologíaspa
dc.titleInflammatory Relapses after Immunosuppressive Drug Discontinuation in Uveitis Patients: A Survival Analysisspa
dc.typejournal articlespa
dspace.entity.typePublication
relation.isAuthorOfPublication0ae30c23-484f-4f13-9a4d-e399c2566789
relation.isAuthorOfPublicationaf8b4da6-c0e8-459a-8f7f-8b365df94d3b
relation.isAuthorOfPublication.latestForDiscovery0ae30c23-484f-4f13-9a4d-e399c2566789

Files